Ischemaview, Inc.: FDA filings under this applicant name
FDA lists 23 510(k) clearances under the applicant name “Ischemaview, Inc.” (first 2013, latest 2026), across 5 product codes in 1 review panel. Median 510(k) review time under this name: 103 days. Since 2017 the median was 98 days, against 129 days for all cleared 510(k)s in the same product codes. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2013 | 1 | 507 |
| 2014 | 0 | — |
| 2015 | 0 | — |
| 2016 | 0 | — |
| 2017 | 0 | — |
| 2018 | 2 | 194 |
| 2019 | 0 | — |
| 2020 | 2 | 93 |
| 2021 | 0 | — |
| 2022 | 4 | 100 |
| 2023 | 4 | 123 |
| 2024 | 3 | 172 |
| 2025 | 6 | 90 |
| 2026 | 1 | 103 |
Review time against the same product codes
Since 2017, 510(k)s cleared under the name Ischemaview, Inc. took a median 98 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 129 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| QAS | Radiological Computer-Assisted Triage And Notification Software | 9 | 9 |
| LLZ | System, Image Processing, Radiological | 6 | 6 |
| QIH | Automated Radiological Image Processing Software | 5 | 5 |
| POK | Computer-Assisted Diagnostic Software For Lesions Suspicious For Cancer | 2 | 2 |
| QFM | Radiological Computer-Assisted Prioritization Software For Lesions | 1 | 1 |
Review panels
- Radiology (23)
Most recent Ischemaview, Inc. 510(k) clearances
| 510(k) | Device | Product code | Decision date | Review days |
|---|---|---|---|---|
| K261085 | Rapid Vessel Occlusion (Rapid VO) | QAS | 2026-07-13 | 103 |
| K251987 | Rapid Aortic Measurements | QIH | 2025-09-23 | 88 |
| K251533 | Rapid Obstructive Hydrocephalus, Rapid OH | QAS | 2025-09-04 | 108 |
| K252526 | Rapid DeltaFuse | LLZ | 2025-08-26 | 15 |
| K251151 | Rapid CTA 360 | QAS | 2025-07-16 | 93 |
| K243378 | Rapid MLS | QIH | 2025-05-28 | 210 |
| K243350 | Rapid Neuro3D | QIH | 2025-01-22 | 86 |
| K233582 | Rapid | LLZ | 2024-04-22 | 172 |
| K232156 | Rapid ASPECTS (v3) | POK | 2024-01-19 | 183 |
| K233512 | Rapid (6.0) | QIH | 2024-01-16 | 76 |
13 earlier clearances. See the full list in Caduvo.
Recalls
openFDA lists no recalls under a recalling firm named Ischemaview, Inc..
Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Other FDA applicant names starting with the same word
FDA records these as separate applicants. Some may belong to the same corporate group and some may not; their filings are not included in the counts above.
- Ischemaview Incorporated (1 510(k)s)
Frequently asked questions
How many FDA 510(k) clearances are listed under Ischemaview, Inc.?
FDA lists 23 510(k) clearances under the applicant name “Ischemaview, Inc.” (first 2013, latest 2026), across 5 product codes in 1 review panel. Filings under other applicant names, such as subsidiaries, are not included.
How long has FDA taken to clear 510(k)s filed by Ischemaview, Inc.?
The median time from FDA receipt to decision across 510(k)s cleared under the name Ischemaview, Inc. is 103 days. Since 2017: 98 days, versus 129 days for all cleared 510(k)s in the same product codes.
Which FDA product codes appear under Ischemaview, Inc.?
The most frequent FDA product codes under this applicant name are QAS (Radiological Computer-Assisted Triage And Notification Software, 9); LLZ (System, Image Processing, Radiological, 6); QIH (Automated Radiological Image Processing Software, 5).
Next steps
- See all 23 Ischemaview, Inc. clearances with predicates and recalls
- Run predicate analysis for product code QAS, Ischemaview, Inc.'s most frequent
Data from openFDA (510(k), PMA, De Novo, device recalls), ClinicalTrials.gov and SEC company tickers. Each page covers one FDA applicant name, with punctuation and legal suffixes removed; filings under other names are not included. Review days run from FDA receipt to decision. Not regulatory advice. Report an error in this data.